Researchers have developed a computational DNA droplet with the ability to recognise specific combinations of chemically synthesised microRNAs that act as biomarkers of tumours.
List view / Grid view
By inhibiting the activity of microRNA-194 (miR-194), scientists prevented prostate cancer cells from developing treatment resistance in vitro.
According to researchers, an interaction between host microRNA and SARS-CoV-2 could be responsible for the range of disease severities.
A team has found that a mutation in the ATAXIN-1 gene causes spinocerebellar ataxia type 1 (SCA1), presenting a drug target for the condition.
Drug Target Review rounds up some of the latest news in COVID-19 vaccine candidate R&D.
Researchers have revealed that the microRNA miR-218-5p promoted hair growth in mice, so is a promising drug target for hair loss.
In lab conditions, a new biomaterial was able to accelerate bone regeneration by boosting an immune response that encourages repair.
Researchers have found that PGE2, a signalling molecule involved in inflammation, promotes colorectal cancer progression through a microRNA and targeting that microRNA could have therapeutic potential.
In a pre-clinical model of multiple sclerosis, orally treating susceptible mice with a microRNA from the diseased gut has prevented the disease.
A microRNA inhibitor has been identified which reduced the sizes of aggressive CNS tumours and improved survival in mice.
A new study has shown a new mechanism of controlling fat production in the body which could lead to new therapies to treat obesity.
This research advances the possibility of reviving the heart's regenerative capacities using microRNAs.
An engineered virus kills cancer cells more effectively than another virus currently used in treatments, according to Hokkaido University researchers...
A team of scientists led by Stanford University School of Medicine has identified a link between how proteins bind to our DNA and how cancer develops. This finding may allow researchers to predict cancer pathways and long-term patient outcomes.
Researchers have pinpointed a single molecule - microRNA-31 (miR-31) - the levels of which predict whether a patient has subtype 1 or subtype 2 of Crohn's disease...